Lung cancer is one of the main causes of cancer incidence and death. Glucose is the largest source of energy for cells. Glucose transporter 1 (GLUT1) is overexpressed in different types of cancer. Given the importance of GLUT1 in the oncogenesis process, it is necessary to conduct research to determine the prognostic value and further therapy of GLUT1 in lung cancer. We collected formalin-fixed tissue paraffin blocks from 43 patients with pulmonary Adenocarcinoma (ADC) and Squamous Cell Carcinoma (SqCC) consisting of 34 men and 9 women, used to investigate the immunohistochemical association of GLUT1 expression. All clinicopathological characteristics were obtained through medical records and pathology archives. In this study, 23 cases (53%) of GLUT1 expression were obtained, while 20 cases (47%) were not expressed (negative). Distribution of immunohistochemical expression based on sex was found as many as 21 positive cases (61,8%) in men and 2 positive cases (22,2%) in women. The mean age of patients with ADC and SqCC was 59,51 years. More than 90% of lung cancer sufferers are over 40 years of age. There was a significant relationship between GLUT1 immunohistochemical expression with cancer stage (p <0,008; OR 10.5), tumor size (p <0,003; OR 18.0) and histopathological type (p <0,003; OR 9,14). From the results of this study, GLUT1 expression in lung cancer can be an indication of the metabolic and vascular requirements of tumors with clinical implications for the survival of patients and lung cancer follow-up therapy plans.

Glucose Transporter 1 (GLUT1)

pulmonary Squamous cell carcinoma

pulmonary Adenocarcinoma